Validation of a PCR method for the detection of mycoplasmas according to European Pharmacopoeia section 2.6.7
Recent publication of a revised section for mycoplasma testing in the European Pharmacopoeia [1] has led to interest in validating a nucleic acid amplification technique (NAT) for use in detection of mycoplasma contaminants in biologics drugs. The replacement by or supplementation of the existing cu...
Gespeichert in:
| Veröffentlicht in: | Biologicals 2010-03, Vol.38 (2), p.232-237 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 237 |
|---|---|
| container_issue | 2 |
| container_start_page | 232 |
| container_title | Biologicals |
| container_volume | 38 |
| creator | Zhi, Yan Mayhew, Amy Seng, Natalie Takle, Garry B. |
| description | Recent publication of a revised section for
mycoplasma testing in the European Pharmacopoeia
[1] has led to interest in validating a nucleic acid amplification technique (NAT) for use in detection of
mycoplasma contaminants in biologics drugs. The replacement by or supplementation of the existing culture-based methods with a PCR-based method has several advantages for the biopharmaceutical industry, mainly with respect to reduced turnaround time for results, and potentially lowered cost. Replacement or substitution of existing methods by a PCR method requires the demonstration of equivalent assay limit of detection (LOD) and specificity. The experimental requirements for this comparability validation have been enumerated in detail in the EP section referenced above. In this publication, we describe the validation and comparability analysis of a PCR method performed exactly according to the EP guidance. Completion of this validation activity has resulted in the availability of an assay that meets or exceeds EP compliance requirements for a
mycoplasma detection method. |
| doi_str_mv | 10.1016/j.biologicals.2009.11.003 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_877568940</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1045105609001754</els_id><sourcerecordid>733852191</sourcerecordid><originalsourceid>FETCH-LOGICAL-c408t-ebd7dec070e2200cbd2888156bb38d29bc4d78dfba44c96ea59afb94b0dacd9c3</originalsourceid><addsrcrecordid>eNqNkU1r3DAQhkVJaT7av1CUU052R7ZsScewpB8QaChtr0If46wW29pI3kL-fbXsJuSWnDSH553RzEPIJYOaAeu_bGob4hjvgzNjrhsAVTNWA7TvyBkD1VWybeBkX_OuYtD1p-Q85w0AY1zwD-S0AcaV6sUZmf6aMXizhDjTOFBD71a_6ITLOno6xESXNVKPC7onYnp0cTuaPJlMjXMx-TDf0yXSm12KWzQzvVubNJlCRQyG5mO0qftafCTvh_Jl_HR8L8ifrze_V9-r25_ffqyubyvHQS4VWi88OhCATdnOWd9IKVnXW9tK3yjruBfSD9Zw7lSPplNmsIpb8MZ55doLcnXou03xYYd50VPIDsfRzBh3WUshul4qDq-Som1l1zDFCqkOpEsx54SD3qYwmfSoGei9Fr3RL7TovRbNmC5aSvbzccrOTuifk08eCrA6AFiu8i9g0tkFnB36kMoBtY_hDWP-A6uxpY8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>733852191</pqid></control><display><type>article</type><title>Validation of a PCR method for the detection of mycoplasmas according to European Pharmacopoeia section 2.6.7</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Zhi, Yan ; Mayhew, Amy ; Seng, Natalie ; Takle, Garry B.</creator><creatorcontrib>Zhi, Yan ; Mayhew, Amy ; Seng, Natalie ; Takle, Garry B.</creatorcontrib><description>Recent publication of a revised section for
mycoplasma testing in the European Pharmacopoeia
[1] has led to interest in validating a nucleic acid amplification technique (NAT) for use in detection of
mycoplasma contaminants in biologics drugs. The replacement by or supplementation of the existing culture-based methods with a PCR-based method has several advantages for the biopharmaceutical industry, mainly with respect to reduced turnaround time for results, and potentially lowered cost. Replacement or substitution of existing methods by a PCR method requires the demonstration of equivalent assay limit of detection (LOD) and specificity. The experimental requirements for this comparability validation have been enumerated in detail in the EP section referenced above. In this publication, we describe the validation and comparability analysis of a PCR method performed exactly according to the EP guidance. Completion of this validation activity has resulted in the availability of an assay that meets or exceeds EP compliance requirements for a
mycoplasma detection method.</description><identifier>ISSN: 1045-1056</identifier><identifier>EISSN: 1095-8320</identifier><identifier>DOI: 10.1016/j.biologicals.2009.11.003</identifier><identifier>PMID: 20149967</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Animals ; Bacteriological Techniques - methods ; Bacteriological Techniques - standards ; Biosafety ; CHO Cells ; Contaminants ; Cricetinae ; Cricetulus ; DNA, Bacterial - analysis ; DNA, Bacterial - isolation & purification ; Europe ; European Pharmacopoeia ; Humans ; Limit of Detection ; Mycoplasma ; Mycoplasma - genetics ; Mycoplasma - isolation & purification ; Mycoplasma Infections - diagnosis ; Mycoplasma Infections - microbiology ; PCR method ; Pharmacopoeias as Topic - standards ; Polymerase Chain Reaction - methods ; Polymerase Chain Reaction - standards ; Reference Standards ; Sensitivity and Specificity ; Species Specificity ; Validation</subject><ispartof>Biologicals, 2010-03, Vol.38 (2), p.232-237</ispartof><rights>2009 The International Association for Biologicals</rights><rights>(c) 2009 The International Association for Biologicals. Published by Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c408t-ebd7dec070e2200cbd2888156bb38d29bc4d78dfba44c96ea59afb94b0dacd9c3</citedby><cites>FETCH-LOGICAL-c408t-ebd7dec070e2200cbd2888156bb38d29bc4d78dfba44c96ea59afb94b0dacd9c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.biologicals.2009.11.003$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3548,27922,27923,45993</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20149967$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zhi, Yan</creatorcontrib><creatorcontrib>Mayhew, Amy</creatorcontrib><creatorcontrib>Seng, Natalie</creatorcontrib><creatorcontrib>Takle, Garry B.</creatorcontrib><title>Validation of a PCR method for the detection of mycoplasmas according to European Pharmacopoeia section 2.6.7</title><title>Biologicals</title><addtitle>Biologicals</addtitle><description>Recent publication of a revised section for
mycoplasma testing in the European Pharmacopoeia
[1] has led to interest in validating a nucleic acid amplification technique (NAT) for use in detection of
mycoplasma contaminants in biologics drugs. The replacement by or supplementation of the existing culture-based methods with a PCR-based method has several advantages for the biopharmaceutical industry, mainly with respect to reduced turnaround time for results, and potentially lowered cost. Replacement or substitution of existing methods by a PCR method requires the demonstration of equivalent assay limit of detection (LOD) and specificity. The experimental requirements for this comparability validation have been enumerated in detail in the EP section referenced above. In this publication, we describe the validation and comparability analysis of a PCR method performed exactly according to the EP guidance. Completion of this validation activity has resulted in the availability of an assay that meets or exceeds EP compliance requirements for a
mycoplasma detection method.</description><subject>Animals</subject><subject>Bacteriological Techniques - methods</subject><subject>Bacteriological Techniques - standards</subject><subject>Biosafety</subject><subject>CHO Cells</subject><subject>Contaminants</subject><subject>Cricetinae</subject><subject>Cricetulus</subject><subject>DNA, Bacterial - analysis</subject><subject>DNA, Bacterial - isolation & purification</subject><subject>Europe</subject><subject>European Pharmacopoeia</subject><subject>Humans</subject><subject>Limit of Detection</subject><subject>Mycoplasma</subject><subject>Mycoplasma - genetics</subject><subject>Mycoplasma - isolation & purification</subject><subject>Mycoplasma Infections - diagnosis</subject><subject>Mycoplasma Infections - microbiology</subject><subject>PCR method</subject><subject>Pharmacopoeias as Topic - standards</subject><subject>Polymerase Chain Reaction - methods</subject><subject>Polymerase Chain Reaction - standards</subject><subject>Reference Standards</subject><subject>Sensitivity and Specificity</subject><subject>Species Specificity</subject><subject>Validation</subject><issn>1045-1056</issn><issn>1095-8320</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkU1r3DAQhkVJaT7av1CUU052R7ZsScewpB8QaChtr0If46wW29pI3kL-fbXsJuSWnDSH553RzEPIJYOaAeu_bGob4hjvgzNjrhsAVTNWA7TvyBkD1VWybeBkX_OuYtD1p-Q85w0AY1zwD-S0AcaV6sUZmf6aMXizhDjTOFBD71a_6ITLOno6xESXNVKPC7onYnp0cTuaPJlMjXMx-TDf0yXSm12KWzQzvVubNJlCRQyG5mO0qftafCTvh_Jl_HR8L8ifrze_V9-r25_ffqyubyvHQS4VWi88OhCATdnOWd9IKVnXW9tK3yjruBfSD9Zw7lSPplNmsIpb8MZ55doLcnXou03xYYd50VPIDsfRzBh3WUshul4qDq-Som1l1zDFCqkOpEsx54SD3qYwmfSoGei9Fr3RL7TovRbNmC5aSvbzccrOTuifk08eCrA6AFiu8i9g0tkFnB36kMoBtY_hDWP-A6uxpY8</recordid><startdate>20100301</startdate><enddate>20100301</enddate><creator>Zhi, Yan</creator><creator>Mayhew, Amy</creator><creator>Seng, Natalie</creator><creator>Takle, Garry B.</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7QL</scope><scope>C1K</scope></search><sort><creationdate>20100301</creationdate><title>Validation of a PCR method for the detection of mycoplasmas according to European Pharmacopoeia section 2.6.7</title><author>Zhi, Yan ; Mayhew, Amy ; Seng, Natalie ; Takle, Garry B.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c408t-ebd7dec070e2200cbd2888156bb38d29bc4d78dfba44c96ea59afb94b0dacd9c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Animals</topic><topic>Bacteriological Techniques - methods</topic><topic>Bacteriological Techniques - standards</topic><topic>Biosafety</topic><topic>CHO Cells</topic><topic>Contaminants</topic><topic>Cricetinae</topic><topic>Cricetulus</topic><topic>DNA, Bacterial - analysis</topic><topic>DNA, Bacterial - isolation & purification</topic><topic>Europe</topic><topic>European Pharmacopoeia</topic><topic>Humans</topic><topic>Limit of Detection</topic><topic>Mycoplasma</topic><topic>Mycoplasma - genetics</topic><topic>Mycoplasma - isolation & purification</topic><topic>Mycoplasma Infections - diagnosis</topic><topic>Mycoplasma Infections - microbiology</topic><topic>PCR method</topic><topic>Pharmacopoeias as Topic - standards</topic><topic>Polymerase Chain Reaction - methods</topic><topic>Polymerase Chain Reaction - standards</topic><topic>Reference Standards</topic><topic>Sensitivity and Specificity</topic><topic>Species Specificity</topic><topic>Validation</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zhi, Yan</creatorcontrib><creatorcontrib>Mayhew, Amy</creatorcontrib><creatorcontrib>Seng, Natalie</creatorcontrib><creatorcontrib>Takle, Garry B.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Environmental Sciences and Pollution Management</collection><jtitle>Biologicals</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zhi, Yan</au><au>Mayhew, Amy</au><au>Seng, Natalie</au><au>Takle, Garry B.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Validation of a PCR method for the detection of mycoplasmas according to European Pharmacopoeia section 2.6.7</atitle><jtitle>Biologicals</jtitle><addtitle>Biologicals</addtitle><date>2010-03-01</date><risdate>2010</risdate><volume>38</volume><issue>2</issue><spage>232</spage><epage>237</epage><pages>232-237</pages><issn>1045-1056</issn><eissn>1095-8320</eissn><abstract>Recent publication of a revised section for
mycoplasma testing in the European Pharmacopoeia
[1] has led to interest in validating a nucleic acid amplification technique (NAT) for use in detection of
mycoplasma contaminants in biologics drugs. The replacement by or supplementation of the existing culture-based methods with a PCR-based method has several advantages for the biopharmaceutical industry, mainly with respect to reduced turnaround time for results, and potentially lowered cost. Replacement or substitution of existing methods by a PCR method requires the demonstration of equivalent assay limit of detection (LOD) and specificity. The experimental requirements for this comparability validation have been enumerated in detail in the EP section referenced above. In this publication, we describe the validation and comparability analysis of a PCR method performed exactly according to the EP guidance. Completion of this validation activity has resulted in the availability of an assay that meets or exceeds EP compliance requirements for a
mycoplasma detection method.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>20149967</pmid><doi>10.1016/j.biologicals.2009.11.003</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1045-1056 |
| ispartof | Biologicals, 2010-03, Vol.38 (2), p.232-237 |
| issn | 1045-1056 1095-8320 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_877568940 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | Animals Bacteriological Techniques - methods Bacteriological Techniques - standards Biosafety CHO Cells Contaminants Cricetinae Cricetulus DNA, Bacterial - analysis DNA, Bacterial - isolation & purification Europe European Pharmacopoeia Humans Limit of Detection Mycoplasma Mycoplasma - genetics Mycoplasma - isolation & purification Mycoplasma Infections - diagnosis Mycoplasma Infections - microbiology PCR method Pharmacopoeias as Topic - standards Polymerase Chain Reaction - methods Polymerase Chain Reaction - standards Reference Standards Sensitivity and Specificity Species Specificity Validation |
| title | Validation of a PCR method for the detection of mycoplasmas according to European Pharmacopoeia section 2.6.7 |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T07%3A46%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Validation%20of%20a%20PCR%20method%20for%20the%20detection%20of%20mycoplasmas%20according%20to%20European%20Pharmacopoeia%20section%202.6.7&rft.jtitle=Biologicals&rft.au=Zhi,%20Yan&rft.date=2010-03-01&rft.volume=38&rft.issue=2&rft.spage=232&rft.epage=237&rft.pages=232-237&rft.issn=1045-1056&rft.eissn=1095-8320&rft_id=info:doi/10.1016/j.biologicals.2009.11.003&rft_dat=%3Cproquest_cross%3E733852191%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=733852191&rft_id=info:pmid/20149967&rft_els_id=S1045105609001754&rfr_iscdi=true |